ArticleThe oncologist2017

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

Rocío García-Carbonero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.